Viewing data from:

BLEOMYCIN SULFATE

ANDA

BLEOMYCIN SULFATE | A065042 | HIKMA PHARMACEUTICALS USA INC

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$26.45

per ea

Lowest NADAC/Unit

$26.45

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00143924001BLEOMYCIN SULFATE 15 UNIT VIAL	$26.45	EA	Generic	—	2026-04-22

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (2 FSS)

Lowest Price

$39.10

Highest Price

$72.51

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00143-9240-01BLEOMYCIN SO4 15UNT/VIL INJ	$39.10	FSS	Hikma Pharmaceuticals USA Inc.	08/14/2026
00143-9241-01BLEOMYCIN SO4 30UNT/VIL INJ	$72.51	FSS	Hikma Pharmaceuticals USA Inc.	08/14/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain3 active DMFs2 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

TAPI NL BVBLEOMYCIN SULFATE

DMF 137841998

ZHEJIANG HISUN PHARMACEUTICAL CO LTDBLEOMYCIN SULFATE USP (PROCESS II)

DMF 263122012

HUBEI HONCH PHARMACEUTICAL CO LTDBLEOMYCIN SULFATE

DMF 426292025

ZHEJIANG HISUN PHARMACEUTICAL CO LTDInactiveBLEOMYCIN SULFATE USP

DMF 129621998

MAYNE PHARMA USA INCInactiveBLEOMYCIN SULFATE

DMF 132541998

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Apr 10, 2003	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 30 UNITS BASE/VIAL

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Oct 17, 2001

No patent or exclusivity listings for this strength.

#002 — EQ 15 UNITS BASE/VIAL

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Oct 17, 2001